In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Shares of Eli Lilly & Co. LLY advanced 1.11% to $915.04 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and ...

Sept 5 (Reuters) - U.S. drugmaker Eli Lilly (LLY.N), opens new tab has signed a research deal with privately held AI-focused firm Genetic Leap to develop genetic medicines, the latter said on ...

U.S. drugmaker Eli Lilly has signed a research deal with privately held AI-focused firm Genetic Leap to develop genetic medicines, the latter said on Thursday. WHY IT'S IMPORTANT Major drugmakers ...

An Eli Lilly insulin engineered for once-weekly dosing now has preliminary results from two more pivotal studies showing the injection was comparable to once-daily insulin, a new slate of data ...

Eli Lilly Partners With AI-Focused Genetic Leap to Develop RNA-Based Drugs (Reuters) -U.S. drugmaker Eli Lilly has signed a research deal with privately held AI-focused firm Genetic Leap to ...

Sept 3 (Reuters) - BioAge Labs, an obesity therapy-focused startup that has also collaborated with Eli Lilly (LLY.N), opens new tab, filed for an initial public offering in the United States on ...

The primary cause for the selloff could be because Eli Lilly (NYSE:LLY) has cut the knees out from under Hims & Hers biggest selling point: selling weight-loss drugs at a steep discount.

Eli Lilly is ramping up its campaign against imitations of its blockbuster appetite-suppressing drugs, seeking to put an end to a regulatory designation that has allowed cheaper, off-brand ...